Summit Therapeutics
SMMT
45 hedge funds and large institutions have $2.88M invested in Summit Therapeutics in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 16 reducing their positions, and 20 closing their positions.
2.59% less ownership
Funds ownership: 11.23% → 8.64% (-2.6%)
13% less funds holding
Funds holding: 52 → 45 (-7)
30% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 20
69% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 16
75% less capital invested
Capital invested by funds: $11.7M → $2.88M (-$8.81M)
Top Buyers
| 1 |
Millennium Management
New York
|
+$641K |
| 2 |
AGM
Alpine Global Management
New York
|
+$421K |
| 3 |
E
Ergoteles
New York
|
+$141K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$79.5K |
| 5 |
Renaissance Technologies
New York
|
+$68.9K |
Top Sellers
| 1 |
BlackRock
New York
|
-$1.49M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$1.07M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$944K |
| 4 |
State Street
Boston,
Massachusetts
|
-$768K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$431K |
SMMT Hedge Fund Activity: Q2 2022 in Review
45 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q2 2022, worth a combined $2.88M — down 75% from $11.7M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SMMT and 14 opened new positions — a net loss of 6 holders — while 16 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $641K. The largest seller was BlackRock, cutting an estimated $1.49M.
- 45 institutional investors held Summit Therapeutics (SMMT) as of Q2 2022, down from 52 in Q1 2022.
- Funds reported $2.88M of Summit Therapeutics stock for Q2 2022, down 75% quarter-over-quarter.
- 14 funds opened new Summit Therapeutics positions in Q2 2022 and 20 closed out, a net change of -6 holders.
- The largest Summit Therapeutics buyer in Q2 2022 was Millennium Management, an estimated $641K added.
- The largest Summit Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.49M sold.
Based on aggregated 13F filings for Q2 2022.